Deal Watch: Sanofi Teams Up With Biond On Novel Checkpoint Inhibitor
Executive Summary
Days after buying Kymab, Sanofi partners with Israel’s Biond on IO candidate targeting ILT2. Gilead again tackles functional cure of hepatitis B in alliance with Vir.